These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 38013475)

  • 1. Reappraisal of Portal Vein Tumor Thrombosis as a Prognostic Factor for Patients with Hepatocellular Carcinoma.
    Chang Y; Yu SJ; Kim HC; Lee YB; Cho EJ; Lee JH; Kim YJ; Chung JW; Yoon JH
    Gut Liver; 2024 Jan; 18(1):156-164. PubMed ID: 38013475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis.
    Lee JM; Jang BK; Lee YJ; Choi WY; Choi SM; Chung WJ; Hwang JS; Kang KJ; Kim YH; Chauhan AK; Park SY; Tak WY; Kweon YO; Kim BS; Lee CH
    Clin Mol Hepatol; 2016 Mar; 22(1):160-7. PubMed ID: 27044767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comparison of therapeutics effects of transcatheter arterial chemoembolization combined with iodine-125 seed implantation and sorafenib for the treatment of hepatocellular carcinoma with portal vein tumor thrombosis].
    Luo J; Zheng JP; Shao GL; Wen S; Guo LW; Zeng H; Zhang L; Qian CY; Hao WY
    Zhonghua Gan Zang Bing Za Zhi; 2018 Apr; 26(4):298-304. PubMed ID: 29996343
    [No Abstract]   [Full Text] [Related]  

  • 4. Combination Therapy of Chemoembolization and Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Compared with Chemoembolization Alone: A Propensity Score-Matched Analysis.
    Liu BJ; Gao S; Zhu X; Guo JH; Kou FX; Liu SX; Zhang X; Wang XD; Cao G; Chen H; Liu P; Zhu LZ; Xu HF; Yang RJ
    Biomed Res Int; 2021; 2021():6670367. PubMed ID: 34337041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognosis Nomogram for Hepatocellular Carcinoma Patients with Portal Vein Invasion Undergoing Transarterial Chemoembolization Plus Sorafenib Treatment: A Retrospective Multicentre Study.
    Zhang L; Sun JH; Hou ZH; Zhong BY; Yang MJ; Zhou GH; Wang WS; Huang P; Zhang S; Li Z; Zhu XL; Yan ZP; Ni CF
    Cardiovasc Intervent Radiol; 2021 Jan; 44(1):63-72. PubMed ID: 32965582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of portal vein tumor thrombosis on survival in patients with hepatocellular carcinoma treated with different therapies: A cohort study.
    Mähringer-Kunz A; Steinle V; Kloeckner R; Schotten S; Hahn F; Schmidtmann I; Hinrichs JB; Düber C; Galle PR; Lang H; Weinmann A
    PLoS One; 2021; 16(5):e0249426. PubMed ID: 33961627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anlotinib followed by transarterial chemoembolization and radiofrequency ablation is a safe and effective initial treatment for hepatocellular carcinoma patients with portal vein tumor thrombus: A retrospective case series study.
    Wang J; Li X; Wang F; Shi D; Zhang J
    J Cancer Res Ther; 2021 Jul; 17(3):619-624. PubMed ID: 34269290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of transarterial chemoembolization plus sorafenib for hepatocellular carcinoma with portal venous tumour thrombus.
    Pan T; Li XS; Xie QK; Wang JP; Li W; Wu PH; Zhao M
    Clin Radiol; 2014 Dec; 69(12):e553-61. PubMed ID: 25304928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatocellular carcinoma with portal vein tumor thrombus: treatment with transarterial chemoembolization combined with sorafenib--a retrospective controlled study.
    Zhu K; Chen J; Lai L; Meng X; Zhou B; Huang W; Cai M; Shan H
    Radiology; 2014 Jul; 272(1):284-93. PubMed ID: 24708192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of hepatocellular carcinoma patients with portal vein tumor thrombosis: A narrative review.
    Tao ZW; Cheng BQ; Zhou T; Gao YJ
    Hepatobiliary Pancreat Dis Int; 2022 Apr; 21(2):134-144. PubMed ID: 34955380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The PPRD score stratifies patients with hepatocellular carcinoma and portal vein tumor thrombus treated with sorafenib plus transarterial chemoembolization.
    Zhang Y; Miao H; Xie W; Jiang S; Song Z; Huang G; Fan W; Wang Y; Li J; Chen Y
    Eur Radiol; 2021 Jan; 31(1):232-243. PubMed ID: 32728770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study.
    Ding X; Sun W; Li W; Shen Y; Guo X; Teng Y; Liu X; Zheng L; Li W; Chen J
    Cancer; 2021 Oct; 127(20):3782-3793. PubMed ID: 34237154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-hepatectomy survival in advanced hepatocellular carcinoma with portal vein tumor thrombosis.
    Yamamoto Y; Ikoma H; Morimura R; Shoda K; Konishi H; Murayama Y; Komatsu S; Shiozaki A; Kuriu Y; Kubota T; Nakanishi M; Ichikawa D; Fujiwara H; Okamoto K; Sakakura C; Ochiai T; Otsuji E
    World J Gastroenterol; 2015 Jan; 21(1):246-53. PubMed ID: 25574098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transarterial chemoembolization in patients with hepatocellular carcinoma beyond Barcelona-Clinic Liver Cancer- B and portal vein tumor thrombosis: Experience from a tertiary care center.
    Anand S; Pottakkat B; Raja K; Chandrasekar S; Satheesh S
    Indian J Cancer; 2022; 59(3):325-329. PubMed ID: 33753610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of endovascular implantation of a portal vein stent combined with iodine-125 seed-strips followed by transcatheter arterial chemoembolization with sorafenib for the treatment of hepatocellular carcinoma with portal vein tumor thrombosis.
    Li S; Li L; Li B; Wang W
    Br J Radiol; 2020 Aug; 93(1112):20190279. PubMed ID: 32464068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined DeRitis ratio and alkaline phosphatase on the prediction of portal vein tumor thrombosis in patients with hepatocellular carcinoma.
    Miao TG; Zhang SY; Zhang YJ; Ma D; Nan YM
    Sci Rep; 2024 Sep; 14(1):21614. PubMed ID: 39284840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival benefit of hepatic resection versus transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis.
    Zhang XP; Wang K; Li N; Zhong CQ; Wei XB; Cheng YQ; Gao YZ; Wang H; Cheng SQ
    BMC Cancer; 2017 Dec; 17(1):902. PubMed ID: 29282010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A study of the clinical profile, predictors, prognostic features, and survival of patients with hepatocellular carcinoma having macroscopic portal vein tumor thrombosis.
    Jearth V; Patil PS; Mehta S; Goel M; Patkar S; Kulkarni S; Shetty N; Ostwal V; Ramaswamy A; Sastri S; Engineer R
    Indian J Gastroenterol; 2022 Dec; 41(6):533-543. PubMed ID: 36715840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of endovascular brachytherapy combined with transarterial chemoembolization for the treatment of hepatocellular carcinoma patients with type III or IV portal vein tumor thrombosis.
    Li L; Cheng N; Huang X; Weng X; Jiao Y; Liu J; Guo W
    World J Surg Oncol; 2022 Feb; 20(1):30. PubMed ID: 35109883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors for survival after transarterial chemoembolization combined with microwave ablation for hepatocellular carcinoma.
    Ni JY; Sun HL; Chen YT; Luo JH; Chen D; Jiang XY; Xu LF
    World J Gastroenterol; 2014 Dec; 20(46):17483-90. PubMed ID: 25516662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.